Although brentuximab vedotin (BV) with cyclophosphamide, doxorubicin, and prednisone has shown clear benefits over CHOP in patients with untreated CD30-positive PTCL, subgroup analysis revealed no advantages of adding BV in patients with AITL and PTCL-NOS17. The gene discussed is TNFRSF8; the disease is mature T-cell and NK-cell non-Hodgkin lymphoma.